By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation; Andrew Ciupek, PhD, Associate Director, Clinical Research; Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research; Heather Law, MA, Associate Director, Lung Cancer Registry; Richard Erwin, Executive Director of the [...]
By Renee Botello MSc, Treatment and Trials Navigator A lung cancer diagnosis can be overwhelming and is life-changing for patients and caregivers. Navigating it is challenging without the correct information. The internet has become many people's primary [...]
Recently, lung cancer professionals from across the globe gathered to connect and discuss developments impacting the lung cancer community at the International Association for the Study of Lung Cancer (IASLC)’s World Conference for Lung Cancer (WCLC) in San Diego, [...]
On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) [...]
On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) who [...]
On October 3, 2024, the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) to be used with platinum-doublet chemotherapy as a treatment before surgery, followed by Opdivo (nivolumab) alone after surgery. This approval is for people with resectable (removable [...]
On September 25, 2024, the U.S. Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for people with unresectable stage 3 (III) non-small cell lung cancer (NSCLC). It’s approved for people who have both: Disease that has not progressed during [...]
On September 19, 2024, the U.S. Food and Drug Administration (FDA) issued a new approval for the targeted therapy drug Rybrevant (amivantamab-vmjw) in combination with the existing combination chemotherapy treatment, Paraplatin (carboplatin) + Alimta (pemetrexed). The FDA approved this [...]
On September 12, 2024, the U.S. Food and Drug Administration (FDA) announced its approval of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Tecentriq (atezolizumab) that [...]
By Brittney Nichols, MPH-RN, Senior Specialist, Science and Research, Andrew Ciupek, PhD, Associate Director, Clinical Research, Courtney Granville, PhD, MSPH, Chief Scientific Officer Receiving a lung cancer diagnosis can be a scary, life-changing experience. While modern medicine has led [...]